A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Latest Information Update: 08 Dec 2018
At a glance
- Drugs Ceralifimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms DreaMS
- Sponsors EMD Serono; Ono Pharmaceutical
- 16 Jul 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 08 Jul 2013 Planned end date changed from 1 Jun 2014 to 1 Jun 2016 as reported by ClinicalTrials.gov.
- 22 Feb 2013 New trial record